Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Importance: Ovarian cancer has the highest mortality rate among gynecologic malignant tumors. Data are lacking on the survival benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with ovarian cancer who underwent primary or interval cytoreductive surgery. Objective: To assess the clinical benefit of HIPEC after primary or interval maximal cytoreductive surgery in women with stage III or IV primary advanced ovarian cancer. Design, Setting, and Participants: In this single-blind randomized clinical trial performed at 2 institutions in South Korea from March 2, 2010, to January 22, 2016, a total of 184 patients with stage III or IV ovarian cancer with residual tumor size less than 1 cm were randomized (1:1) to a HIPEC (41.5 °C, 75 mg/m2 of cisplatin, 90 minutes) or control group. The primary end point was progression-free survival. Overall survival and adverse events were key secondary end points. The date of the last follow-up was January 10, 2020, and the data were locked on February 17, 2020. Exposures: Hyperthermic intraperitoneal chemotherapy after cytoreductive surgery. Main Outcomes and Measures: Progression-free and overall survival. Results: Of the 184 Korean women who underwent randomization, 92 were randomized to the HIPEC group (median age, 52.0 years; IQR, 46.0-59.5 years) and 92 to the control group (median age, 53.5 years; IQR, 47.5-61.0 years). After a median follow-up of 69.4 months (IQR, 54.4-86.3 months), median progression-free survival was 18.8 months (IQR, 13.0-43.2 months) in the control group and 19.8 months (IQR, 13.7-55.4 months) in the HIPEC group (P = .43), and median overall survival was 61.3 months (IQR, 34.3 months to not reported) in the control group and 69.5 months (IQR, 45.6 months to not reported) in the HIPEC group (P = .52). In the subgroup of interval cytoreductive surgery after neoadjuvant chemotherapy, the median progression-free survival was 15.4 months (IQR, 10.6-21.1 months) in the control group and 17.4 months (IQR, 13.8-31.5 months) in the HIPEC group (hazard ratio for disease progression or death, 0.60; 95% CI, 0.37-0.99; P = .04), and the median overall survival was 48.2 months (IQR, 33.8-61.3 months) in the control group and 61.8 months (IQR, 46.7 months to not reported) in the HIPEC group (hazard ratio, 0.53; 95% CI, 0.29-0.96; P = .04). In the subgroup of primary cytoreductive surgery, median progression-free survival was 29.7 (IQR, 17.2-90.1 months) in the control group and 23.9 months (IQR, 12.3-71.5 months) in the HIPEC group, and the median overall survival was not reached in the control group and 71.3 months (IQR, 45.6 months to not reported) in the HIPEC group. Conclusions and Relevance: The addition of HIPEC to cytoreductive surgery did not improve progression-free and overall survival in patients with advanced epithelial ovarian cancer. Although the results are from a subgroup analysis, the addition of HIPEC to interval cytoreductive surgery provided an improvement of progression-free and overall survival. Trial Registration: ClinicalTrials.gov Identifier: NCT01091636.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Arnold, M., Rutherford, M. J., Bardot, A., Ferlay, J., Andersson, T. M.-L., Myklebust, T. Å., Tervonen, H., Thursfield, V., Ransom, D., Shack, L., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30456-5 · Cited by 1,063
Use of CA-125 to Define Progression of Ovarian Cancer in Patients With Persistently Elevated Levels
Rustin, G. J. S., Marples, M., Nelstrop, A. E., Mahmoudi, M., & Meyer, T. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.20.4054 · Cited by 201 · cited 1×
“5) 17 (13-23) 15 (13-29) 16 (14-22) 14 (12-20) 17 (13-27)”
Cited by
Caruso, G., Weroha, S. J., & Cliby, W. (2025) · JAMA · doi:10.1001/jama.2025.9495 · Cited by 304
Metadata
- Authors
- Lim, M. C., Chang, S.-J., Park, B., Yoo, H. J., Yoo, C. W., Nam, B. H., Park, S.-Y., Collaborators, H. F. O. C., Seo, S.-S., Kang, S., Yun, J. Y., Cho, D.-S., Kim, S. H., Kim, T.-S., Park, S. S., Lee, D. W., Park, S. C., Park, H. M., Han, S.-S., Kim, S. H., Yang, H. C., Kim, M. S., Lee, J. M., Eom, B. W., Kim, Y. I., Yoon, H. M., Choi, I. J., Kim, S. H., Joung, J. Y., Seo, H. K., Joo, J. N., Song, Y. J., Park, S. H., Jung, D. C., Kim, M. J., Park, J. W., Jeong, S.-Y., Yun, Y. H., Park, S., & Bristow, R. E.
- Venue
- JAMA Surgery
- Publisher
- American Medical Association (AMA)
- Published
- 2022-05-01
- Volume
- 157
- Issue
- 5
- Pages
- 374
- ISSN
- 2168-6254 (ISSN-L)
- OpenAlex
- W4220935310
- Cited by
- 221
- References
- 4
- FWCI
- 32.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamasurg.2022.0143
- The paper
- Lim, M. C., Chang, S.-J., Park, B., Yoo, H. J., Yoo, C. W., Nam, B. H., Park, S.-Y., Collaborators, H. F. O. C., Seo, S.-S., Kang, S., Yun, J. Y., Cho, D.-S., Kim, S. H., Kim, T.-S., Park, S. S., Lee, D. W., Park, S. C., Park, H. M., Han, S.-S., . . . Bristow, R. E. (2022). Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial. JAMA Surgery. https://doi.org/10.1001/jamasurg.2022.0143
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.